Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | LPL | P06858 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19454689 | 0.79 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL22841184 | 0.77 | MEN1 (0.39) | MEN1KMT2AKDM4EMAPTRECQL | |
| SCHEMBL154802 | 0.72 | CA2 (0.42) | CA2LPLLIPG | |
| SCHEMBL850564 | 0.72 | — | — | |
| SCHEMBL30693631 | 0.71 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL212497 | 0.71 | CA2 (0.38) | CA2LPLLIPG | |
| SCHEMBL29802448 | 0.71 | CA2 (0.38) | CA2LPLLIPG | |
| SCHEMBL25405416 | 0.70 | ENPP2 (0.39) | MEN1KMT2ACA2KDM4EMAPT | |
| SCHEMBL533039 | 0.70 | MEN1 (0.31) | MEN1KMT2A | |
| Water SCHEMBL1961682 | 0.70 | CA2 (0.37) | CA2LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768675-B1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2026-04-01 | — | — | EP | disclosed |
| EP-4603109-A1 | ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-08-20 | — | — | EP | disclosed |
| EP-4603487-A1 | HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-08-20 | — | — | EP | disclosed |
| EP-4596550-A1 | COMPOUND USABLE IN CONJUGATION REACTION AND CONJUGATE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-08-06 | — | — | EP | disclosed |
| US-20250161474-A1 | ANTIBODY-DRUG CONJUGATES TARGETING EGFR/C-MET AND PREPARATION METHODS AND USES THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-05-22 | — | — | US | disclosed |
| US-11780830-B2 | Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same | YUHAN CORPORATION (KR) | 2023-10-10 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-109415381-B | Thiazolopyridine derivatives as GPR119 agonists | 人类制药有限公司 | 2022-03-25 | — | — | CN | disclosed |
| US-20210317110-A1 | TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2021-10-14 | — | — | US | disclosed |
| CN-113227095-A | Novel tricyclic compounds as IRAK4 inhibitors | 韩国化学研究院 | 2021-08-06 | — | — | CN | disclosed |
| US-20070082900-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
| US-20070082900-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
| US-20070072881-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-29 | — | — | US | disclosed |
| US-20070072881-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2007-03-29 | — | — | US | disclosed |
| EP-1244617-B1 | SUBSTITUTED AMINOALKYLAMIDE DERIVATIVES AS ANTAGONISTS OF FOLLICLE STIMULATING HORMONE | ORTHO MCNEIL PHARM INC (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20040092505-A1 | Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone | COATS STEVEN J (US) | 2004-05-13 | — | — | US | disclosed |
| US-6583179-B2 | For therapy of uterine fibroids, endometriosis, polycystic ovarian disease, dysfunctional uterine bleeding, breast cancer and ovarian cancer; depletion of oocytes; spermatocyte depletion; for female and male contraception | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-06-24 | — | — | US | disclosed |
| EP-1244617-A1 | SUBSTITUTED AMINOALKYLAMIDE DERIVATIVES AS ANTAGONISTS OF FOLLICLE STIMULATING HORMONE | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020058654-A1 | Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-05-16 | — | — | US | disclosed |
| WO-2001047875-A1 | SUBSTITUTED AMINOALKYLAMIDE DERIVATIVES AS ANTAGONISTS OF FOLLICLE STIMULATING HORMONE | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058654-A1 | Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone | FSHR, GNRHR, SHBG | MEN1 4221/4885KMT2A 556/4885CA2 3056/4885 |
| US-20210317110-A1 | TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | SLC10A1, VAT1, LIPC | MEN1 3747/4885KMT2A 4675/4885CA2 4795/4885 |
| US-11780830-B2 | Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same | SLC10A1, VAT1, LIPC | MEN1 3747/4885KMT2A 4675/4885CA2 4795/4885 |
| US-20070082900-A1 | Methods for inhibiting protein kinases | PIM1, AURKC, PIM3 | MEN1 2806/4885KMT2A 1517/4885CA2 3474/4885 |
| US-20250161474-A1 | ANTIBODY-DRUG CONJUGATES TARGETING EGFR/C-MET AND PREPARATION METHODS AND USES THEREOF | MET, EGFR, ERBB2 | MEN1 408/4885KMT2A 922/4885CA2 3267/4885 |
| US-20040092505-A1 | Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone | FSHR, GNRHR, SHBG | MEN1 4221/4885KMT2A 556/4885CA2 3056/4885 |
| US-20070072881-A1 | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors | CDK2, CDK1, CDKN1A | MEN1 3191/4885KMT2A 1051/4885CA2 3460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.